

Clinical Policy: Naloxegol (Movantik)

Reference Number: HIM.PA.167

Effective Date: 06.01.23

Last Review Date: 11.25

Line of Business: HIM

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Naloxegol (Movantik[®]) is an opioid antagonist.

FDA Approved Indication(s)

Movantik is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Movantik is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Opioid-Induced Constipation** (must meet all):

1. Diagnosis of OIC;
2. Age $\geq$ 18 years;
3. Member has been taking opioid(s) for $\geq$ 4 weeks due to chronic pain not caused by active cancer;
4. Dose does not exceed both of the following (a and b):
 - a. 25 mg per day;
 - b. 1 tablet per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace.

II. Continued Therapy

A. Opioid-Induced Constipation (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member continues to receive opioid therapy;
3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed both of the following (a and b):
 - a. 25 mg per day;
 - b. 1 tablet per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PA.154 for health insurance marketplace, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

OIC: opioid-induced constipation

Appendix B: Therapeutic Alternatives
Not applicable.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
 - Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole)
 - Known serious or severe hypersensitivity reaction to Movantik or any of its excipients
- Boxed warning(s): none reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
OIC	25 mg PO QD; if not tolerated, reduce to 12.5 mg PO QD	25 mg/day

VI. Product Availability

Tablets: 12.5 mg and 25 mg

VII. References

1. Movantik Prescribing Information. Wilmington, DE; AstraZeneca Pharmaceuticals LP; March 2023. Available at: <https://www.movantik.com/>. Accessed July 15, 2025.
2. Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: Pathophysiology, clinical consequences, and management. *Gastroenterology Research and Practice*. 2014;2014:141737. doi:10.1155/2014/141737.
3. Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. *Pain Med*. 2015;16(12):2324-37.
4. Pergolizzi JV, Raffa RB, Pappagallo M, et al. Peripherally acting μ -opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. *Patient preference and adherence*. 2017;11:107-119. doi:10.2147/PPA.S78042.
5. Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. *Therap Adv Gastroenterol*. 2015;8(4):206-20.
6. Nelson AD, Camilleri M. Opioid-induced constipation: advances and clinical guidance. *Ther Adv Chronic Dis*. 2016; 7(2): 121–134.
7. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier; 2020. Available at: <http://www.clinicalkey.com/pharmacology>.
8. Camilleri M, Lembo A, Katzka DA. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. *Clin Gastroenterol Hepatol*. 2017;15(9):1338-1349.
9. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guidelines on the medical management of opioid-induced constipation. *Gastroenterol*. 2019;156:218-226.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created per February SDC.	02.21.23	05.23
4Q 2023 annual review: no significant changes; references reviewed and updated.	07.06.23	11.23
4Q 2024 annual review: no significant changes; references reviewed and updated.	07.15.24	11.24
4Q 2025 annual review: changed initial approval duration from 6 to 12 months; references reviewed and updated.	07.15.25	11.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2023 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.